Clinical response and patient's tolerance of vaginal versus oral bromocriptine in women who suffers hyperprolactinaemia
Elsayed mostafa, M., esmaiel, A., nossir, W., abdelfattah, M. (2021). Clinical response and patient's tolerance of vaginal versus oral bromocriptine in women who suffers hyperprolactinaemia. EKB Journal Management System, 27(2), 334-342. doi: 10.21608/zumj.2019.14882.1415
Mona Gamal Elsayed mostafa; anwer ezzat esmaiel; wael sabry nossir; mostafa taha abdelfattah. "Clinical response and patient's tolerance of vaginal versus oral bromocriptine in women who suffers hyperprolactinaemia". EKB Journal Management System, 27, 2, 2021, 334-342. doi: 10.21608/zumj.2019.14882.1415
Elsayed mostafa, M., esmaiel, A., nossir, W., abdelfattah, M. (2021). 'Clinical response and patient's tolerance of vaginal versus oral bromocriptine in women who suffers hyperprolactinaemia', EKB Journal Management System, 27(2), pp. 334-342. doi: 10.21608/zumj.2019.14882.1415
Elsayed mostafa, M., esmaiel, A., nossir, W., abdelfattah, M. Clinical response and patient's tolerance of vaginal versus oral bromocriptine in women who suffers hyperprolactinaemia. EKB Journal Management System, 2021; 27(2): 334-342. doi: 10.21608/zumj.2019.14882.1415

Clinical response and patient's tolerance of vaginal versus oral bromocriptine in women who suffers hyperprolactinaemia

Zagazig University Medical Journal
Article 231, Volume 27, Issue 2, March 2021, Page 334-342  XML PDF (590.52 K)
Document Type: Original Article
DOI: 10.21608/zumj.2019.14882.1415
View on SCiNiTO View on SCiNiTO
Authors
Mona Gamal Elsayed mostafa email 1; anwer ezzat esmaiel2; wael sabry nossir3; mostafa taha abdelfattah4
1Obstetrics and gynecology, faculty of medicine, Zagazig university, Egypt
2obstetric and gynecology. faculty of medicine. zagazig university. zagazig. egypt
3obstetric and gynecology. faculty of medicine. zagazig univeristy. mitghamer. egypt
4obstetric and gynecology. faculty of medicine. zagazig universty. mitghamer. egypt
Abstract
Hyperprolactinaemia is areal challenge for gynecologist and endocrinologists ,bromocriptine was used for treating hyperprolactinaemia ,bromocriptine associated with many side effect this study aimed to compare clinical response , side effects and tolerability of vaginal versus oral bromocriptine for treatment of hyperprolactinemia
Patients and methods: Non randomized controlled clinical trial at the out-patient Clinic of Obstetrics and Gynecology,Zagazig University and Zifta general hospital (ministry of health). This study included 87 patients who suffered hyperprolactinaemia .Patients divided into 3 groups:Group A included 29 patients who used bromocriptine 2.5mg tablets vaginally once daily for one month .Group B included 29 patients who administrated bromocriptine 2.5mg vaginal suppositories once daily for one month. Group C included 29 patients who received bromocriptine 2.5mg tablet orally twice daily for one month.Serum prolactin was measured before and after therapy in all cases.
Results:Bromocriptine was effective in decreasing level of prolactin whether used orally or vaginally. Vaginal bromocriptine suppositories application was associated with minimal side effect both local and general .Nausea was the most frequent side effect with oral tablets ,while excessive vaginal discharge and dyspareunia was the most occurring local side effect. Most side effect in three groups occur within the first 10 day after starting therapy.
Conclusions: Bromocriptine is avery effective drug in treating hyperprolactinaemia, restoration of normal ovulation ,improvement of mastalgia and galactorrhea .Based on our results vaginal bromocriptine suppositories is associated with minimal local and systemic side effect when compared with bromocriptine tablets when used orally or vaginally.
Key words: Hyperprolactinaemia ,Bromocriptine, oral, vagina.
Keywords
Hyperprolactinaemia; Oral; vaginal; bromocriptine
Statistics
Article View: 409
PDF Download: 998